Notable Labs

Notable Labs Market Cap per Employee

The Market Cap per Employee of Notable Labs (NTBLQ) as of Nov 8, 2026 is 13.80 USD. In the previous year, Market Cap per Employee was 13.80 USD — a change of 0.00% (lower).

Market Cap per Employee

13.80USD

YoY

0.00%

Last updated:

Market Cap per Employee of Notable Labs is 2023 13.80 USD. Market Cap per Employee of Notable Labs was 2022 13.80 USD. It decreases by 0.00% lower compared to the previous year.

The Notable Labs Market Cap per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market Cap per Employee
Date
Market Cap per Employee
Jan 1, 2016
13.80 USD
Jan 1, 2017
13.80 USD
Jan 1, 2018
13.80 USD
Jan 1, 2019
13.80 USD
Jan 1, 2020
13.80 USD
Jan 1, 2021
13.80 USD
Jan 1, 2022
13.80 USD
Jan 1, 2023
13.80 USD
The Notable Labs Market Cap per Employee history
YEARMarket Cap per EmployeeYoY
13.80USD0.00%
13.80USD0.00%
13.80USD0.00%
13.80USD0.00%
13.80USD0.00%
13.80USD0.00%
13.80USD0.00%
13.80USD0.00%
13.80USD0.00%
13.80USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Market Cap per Employee of Notable Labs is 13.80 USD in 2023.

Market Cap per Employee of Notable Labs changed from 13.80 USD to 13.80 USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Market Cap per Employee Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Market cap per employee shows the market value attributed to each employee. Technology companies typically have higher values due to intellectual capital.

Market Cap per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Market Cap per Employee's Notable Labs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Notable Labs

All Key Metrics — Notable Labs